Three International Towers
Level 24 300 Barangaroo Avenue
Sydney, NSW 2000
Australia
https://www.kaziatherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. John Edwin Friend II, M.D. | CEO, MD & Director | 739.51k | N/A | 1970 |
Ms. Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer | 180.61k | N/A | N/A |
Ms. Anna Sandham | Company Secretary | N/A | N/A | N/A |
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.